Refine your search

Search Results within category "Neurology"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Neurology"


3 Study Matches

EAT-10 Implementation in Amyotrophic Lateral Sclerosis (ALS) Clinic

This study will evaluate the implementation of a clinical tool (EAT-10) within the Penn State Hershey ALS Center. Participation in the study requires completion of 2 surveys - one during an ALS clinic visit and another one 6 weeks later. This will be repeated at up to 10 visits.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least 18 years old
Diagnosed with motor neuron disease, including but not limited to amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), or progressive muscular atrophy (PMA)
Receive care at the Penn State Hershey ALS Center
Exclusion Criteria:
Significant cognitive impairment
Neurology
  Email this study information to me
  Contact the study team

Site for Therapy in Amyotrophic Lateral Sclerosis (TAME)

This is a phase IIB multi-centered, double blind, placebo controlled study to assess the safety and efficacy of a medication called memantine in people with ALS. This study is designed to validate the preliminary data that suggests memantine can slow down the course of ALS and also to determine if memantine can improve ALS patients who have characteristics of frontotemporal dementia.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02118727
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-85
Diagnosed with amyotrophic lateral sclerosis (ALS)
ALS Functional Rating Scale (ALSFRS-R) score > 25
Has a caregiver willing to help with study activities
Exclusion Criteria:
Forced vital capacity (FVC) ≤ 60% predicted
ALS-related weakness for more than 3 years
History of liver disease
Kidney failure
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to test if an experimental drug called edaravone is safe and well tolerated in patients with ALS. In this study, you will receive an oral form of edaravone (a liquid solution that you will swallow). This oral formulation is considered experimental, as it has not been approved to treat ALS. The IV (intravenous) form of edaravone has been approved as a treatment for ALS. The IV form was approved in 2017 by the U.S. Food and Drug Administration (“FDA”). It is known by its commercial-brand name, Radicava, and its generic name, edaravone.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04165824
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-75
Forced vital capacity ≥ 70% predicted
ALS symptom onset within 3 years
Exclusion Criteria:
Undergoing treatment for cancer
Pregnancy or lactation
Hereditary fructose intolerance
Unable to take medications orally
History of hypersensitivity to edaravone
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA